Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

SIM0505

Antibody-drug conjugate · Cytotoxic, directed at cadherin-6 (CDH6) · developed by NextCure

Phase 1 Most advanced trial
NXTC Developer
1 Registered trials

What is SIM0505?

SIM0505 is an antibody-drug conjugate in which an anti-CDH6 monoclonal antibody is linked by a cleavable linker to CPT116, a camptothecin derivative. The antibody binds cadherin-6 on CDH6-expressing tumor cells, and the released payload inhibits DNA topoisomerase I, causing DNA breaks and apoptosis. It is being studied in advanced solid tumors, platinum-resistant ovarian cancer, fallopian tube cancer, renal cell carcinoma, uterine serous carcinoma, primary peritoneal cancer and non-small cell lung cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Antibody-drug conjugate
Targets
cadherin-6 (CDH6), DNA topoisomerase I (TOP1) (secondary target)
Mechanism
Cytotoxic, directed at cadherin-6 (CDH6)
Pathways
DNA replication inhibition, apoptosis induction
Therapy area
Oncology
Developer
NextCure, Inc. (NXTC)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06792552 Phase 1 Advanced Solid Tumors Recruiting NXTC

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid TumorsFallopian Tube CancerNSCLC (Non-small Cell Lung Cancer)Papillary Renal Cell Carcinoma (Prcc)Platinum Resistant Ovarian CancerPrimary Peritoneal CancerRenal Cell Carcinoma (RCC)Uterine Serous Carcinoma (USC)

Other drugs acting on CDH6

More from NextCure

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the NXTC page.

Follow NXTC, the company behind SIM0505

See NXTC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NXTC catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.